Pembrolizumab Found Beneficial in Persistent, Metastatic, or Recurrent Cervical Cancer
Experts at the SGO Annual Meeting on Women's Oncology revealed adding pembrolizumab to chemotherapy ± bevacizumab provides statistically significant, clinically meaningful OS and PFS improvements in women with persistent, recurrent, or metastatic cervical cancer.
Investigators at the 2022 Annual Meeting on Women's Oncology announce the efforts made thus far from the phase III double-blind KEYNOTE-826 trial, led by Nicoletta Colombo, MD, alongside co-investigators.
In the United States, pembrolizumab in combination with chemotherapy, with or without bevacizumab, is approved for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. The meeting presentation included data for patients with any level of PD-L1 expression.
"Adding pembrolizumab to chemotherapy ± bevacizumab provides statistically significant, clinically meaningful OS and PFS improvements in women with persistent, recurrent, or metastatic cervical cancer," stated investigators.
Moreover- a significant benefit was observed in all protocol-specified primary analysis populations (PD-L1 CPS ≥1, all-comer, and CPS ≥10), as well as noting benefit was generally consistent across all protocol-specified subgroups, including the with and without bevacizumab subgroups.
Safety profile for pembrolizumab plus chemotherapy ± bevacizumab was identified as manageable. investigators abserved AEs as expected based on profiles of individual drugs
In conclusion, pembrolizumab plus chemotherapy with or without bevacizumab may be a new standard of care for women with persistent, recurrent, or metastatic cervical cancer.
